Evidence map›Paper›PMID 42149183›Full record

ReviewRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2026

Christopher M Waldmann, Klaus Kopka, Stefan Wagner

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher M WaldmannDepartment of Nuclear Medicine, University Medical Center Mainz, Mainz, Germany. christopher.waldmann@fuzionaire.com.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Stefan WagnerDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-invasive molecular imaging of cancer by means of the hybrid imaging modalities PET/CT and PET/MRI represents a powerful diagnostic tool in modern nuclear medicine. Radiotracers labeled with the prominent positron-emitter fluorine-18 are routinely used to target and visualize distinct biological structures dysregulated in the progression of cancer. Such tracers are therefore capable of detecting oncological pathologies in vivo at the cellular and subcellular levels in a timely manner and are thereby used for early detection of cancer as well as monitoring for treatment response in a personalized manner. This chapter describes a variety of important

Indexed as

Fluorine RadioisotopesNeoplasmsPositron-Emission TomographyRadiopharmaceuticalsAnimalsHumansMolecular WeightFluorine-18Fluorine RadioisotopesRadiopharmaceuticalsCancer diagnosisfluorine-18PET tracersRadiosynthesis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.